Fischer Medical Ventures Ltd has commenced a postal ballot process to secure shareholder approval for the proposed issuance of senior, secured, rated, listed, redeemable, taxable, transferable non-convertible debentures (NCDs) on a private placement basis. The aggregate issue size is capped at ₹350 crore, with voting open from October 17 to November 15, 2026.

The resolutions seek consent for multiple security arrangements to enhance the creditworthiness of the debt instrument. Key approvals include creating a first-ranking pari passu floating charge over the present and future assets of two Indian material wholly owned subsidiaries: Time Medical International Ventures (India) Private Limited and Flynncare Health Innovations Private Limited. Additionally, shareholders are asked to approve the pledge of equity shares held by the promoters and holding company as collateral.

Security Structure and Pledges

The proposed NCD issuance requires robust security cover to satisfy debenture holders and trustees. The company has outlined specific mechanisms for maintaining this cover, including mark-to-market adjustments on pledged shares.

Under Item No. 2, a first-ranking exclusive upfront pledge will be created over such number of equity shares held by Mr. Shankar Varadarajan and/or FMV Holdings Pte. Ltd. as required to maintain a minimum security cover of 2.5 times the outstanding NCD amount. This cover is calculated based on the trailing 30-day average market-to-market price or the latest closing price, whichever is lower. If the security cover falls below 2.25 times, the promoters must pledge additional shares within seven working days to restore it to at least 2.5x.

Borrowing Limits and Corporate Guarantees

Beyond the specific NCD security package, the board has sought broader borrowing powers. Item No. 6 and Item No. 7 request approval under Sections 180(1)(a) and 180(1)(c) of the Companies Act, 2013, respectively. These resolutions authorize the board to create charges on company assets and borrow monies up to an aggregate limit of ₹1,000 crore. This limit applies to all outstanding borrowings, including loans, debentures, and external commercial borrowings, excluding temporary loans from bankers in the ordinary course of business.

Two corporate guarantees are also part of the proposal. FMV Holdings Pte. Ltd., the holding company, and Mercatus Capital Pte. Ltd., a promoter group company, have agreed to provide unconditional and irrevocable guarantees for the full ₹350 crore issue size, along with interest and other costs. These guarantees are offered on a joint and several basis with other guarantors.

What the Numbers Show

A critical observation from the disclosures is the significant reliance on related-party support for this debt raise. The value of the proposed transactions involving the pledge of promoter shares represents 250% of the listed entity's annual consolidated turnover for the immediately preceding financial year. Furthermore, the corporate guarantees from the holding companies are classified as material related-party transactions (RPTs), with the FMV Holdings guarantee amounting to 15.32% of its latest available turnover. This high ratio indicates that the debt capital access is heavily dependent on the balance sheet strength and credit support of the promoter group entities rather than solely on the standalone operational cash flows of Fischer Medical Ventures.

Fischer Medical Ventures Limited declared all four resolutions passed at its 33rd Annual General Meeting held on September 29, 2026. The scrutinizer’s report confirms near-unanimous shareholder support for the adoption of financial statements, dividend declaration, and board appointments.

The meeting, conducted via Video Conferencing from 11:00 am to 11:59 am IST, saw 61 members participate remotely. National Securities Depositories Limited provided the e-voting infrastructure. Mr. Nuren Lodaya, a practising company secretary, served as the scrutinizer and submitted the consolidated report on October 1, 2026.

Voting results and resolutions

Shareholders voted on four key items. The adoption of audited standalone and consolidated financial statements for FY26 received 46,39,30,608 votes in favor against just 20 votes against. Similarly, the declaration of a dividend of ₹0.05 per equity share (5% of face value) was approved with identical vote counts.

The re-appointment of Ms. Svetlana Rao as Whole-Time Director passed with 46,39,30,408 votes in favor and 220 against. The special resolution for the appointment of Mr. David Yeow as Independent Director for a five-year term secured 46,39,27,199 votes in favor and 3,429 against.

Board participation and governance

A significant portion of the board participated from international locations, reflecting the company's global operational footprint. Key managerial personnel joined from various Indian cities to address shareholder queries regarding performance and strategy.

Shareholder engagement topics

During the question-and-answer session, two speaker shareholders raised queries concerning the group's strategic direction. Management, including the Chief Operating Officer and Chief Financial Officer, responded to inquiries on several critical operational metrics.

• International operations and growth opportunities
• Standalone versus consolidated financial performance
• Research and development initiatives
• Capital allocation and strategic priorities
• Working capital management and debtor cycles
• Liabilities structure and operating cash flows
• Business guidance and competitive positioning

The auditors' report and secretarial audit report contained no qualifications or adverse remarks, which were taken as read during the proceedings.